THQ: A High-Yield Healthcare Fund for Monthly Dividend Investors

Dividend investors searching for dependable monthly income often gravitate toward utilities, real estate investment trusts, business development companies, and bond funds. Healthcare investments, by comparison, are usually associated more with long-term growth than high current income.

The Aberdeen Healthcare Opportunities Fund, trading under the ticker THQ, offers investors a way to combine healthcare exposure with a double-digit monthly distribution yield.

However, THQ is not a traditional dividend-paying stock. It is an actively managed closed-end fund, or CEF. That distinction is important because its distributions may come from investment income, capital gains, or return of capital—not simply from dividends generated by the companies it owns.

As of July 10, 2026, THQ traded at $18.99 per share and paid a monthly distribution of $0.18, producing a market distribution rate of approximately 11.45%. Its net asset value was $20.14, meaning investors could purchase the portfolio at a 5.71% discount to NAV.

What Does THQ Invest In?

THQ’s objective is to provide current income alongside long-term capital appreciation. The fund invests across the healthcare industry and can hold common stocks, preferred securities, corporate debt, private investments, and healthcare-related real estate.

Unlike the Aberdeen World Healthcare Fund, or THW, THQ is more heavily concentrated in U.S. healthcare companies. The source video described THQ as the more domestically focused of the two funds, with more recognizable U.S. holdings, somewhat greater healthcare REIT exposure, and fewer venture-stage investments. It also noted that THQ has historically produced the stronger total return of the two healthcare funds.

As of May 31, 2026, THQ held approximately 108 investments. Some of its largest positions included:

• UnitedHealth Group

• Merck

• Abbott Laboratories

• Thermo Fisher Scientific

• Medtronic

• Danaher

• Intuitive Surgical

The portfolio also included private and less-established healthcare companies, such as Veradermics, along with securities from companies outside the United States. Approximately 77.7% of the portfolio’s equity exposure was allocated to the United States, reinforcing THQ’s primarily domestic orientation.

This diversified approach gives shareholders exposure to several healthcare subsectors, including pharmaceuticals, biotechnology, medical devices, managed care, life-science tools, healthcare services, and healthcare real estate.

THQ’s Monthly Distribution

THQ currently pays shareholders $0.18 per share each month, equal to $2.16 annually.

The fund’s distribution was previously $0.1125 per month. In February 2024, its board approved an increase to $0.18—a substantial 60% raise. THQ has maintained that higher payment since the increase.

For an investor holding 1,000 shares, the current distribution would provide:

$180 per month, or $2,160 annually, before taxes.

That level of monthly cash flow makes THQ attractive to retirees and other income-focused investors. Nevertheless, investors should understand that a closed-end fund’s distribution is different from a corporate dividend.

THQ operates under a managed distribution policy. The fund seeks to pay its distribution from current investment income, supplemented by realized capital gains and, when necessary, paid-in capital or return of capital. The board regularly reviews the payment and may change, suspend, or terminate the policy.

In other words, the distribution is not guaranteed simply because it has remained stable.

Is the Distribution Covered?

Distribution coverage is one of the most important considerations when evaluating a high-yield closed-end fund.

For THQ’s June 2026 distribution, Aberdeen estimated that:

• 36% came from net realized short-term gains.

• 46% came from net realized long-term gains.

• 18% was classified as return of capital.

• None was attributed to net investment income.

The same estimated percentages applied to THQ’s fiscal-year-to-date distributions through June 2026. Final tax classifications may change when shareholders receive their Form 1099-DIV.

Return of capital is not automatically negative. It can sometimes reflect tax-efficient accounting, unrealized appreciation, or differences between tax and financial reporting. However, destructive return of capital occurs when a fund repeatedly pays shareholders more than its portfolio earns while its NAV steadily declines.

That makes THQ’s NAV performance especially important.

For the five-year period ending May 31, 2026, THQ produced an average annual total return on NAV of approximately 3.28%. At the same time, its annualized distribution rate on NAV was approximately 12.13%.

The gap does not prove that an immediate reduction is coming. Healthcare investments can experience multiyear cycles, and realized gains can vary significantly from year to year. Still, a distribution rate that remains substantially higher than long-term NAV returns can be difficult to maintain indefinitely without eroding the fund’s asset base.

Dividend investors should therefore monitor THQ’s NAV trend rather than judging the investment solely by its monthly payment.

The Potential Benefits of THQ

THQ offers several qualities that may appeal to income investors.

High Monthly Income

The fund’s approximately 11.45% market distribution rate is considerably higher than the dividend yield available from most individual healthcare companies.

Healthcare Diversification

Many high-income portfolios are heavily concentrated in utilities, real estate, energy, financial companies, and below-investment-grade credit. THQ provides exposure to healthcare businesses that may respond differently to economic conditions.

Exposure to Growth-Oriented Healthcare Companies

THQ owns companies involved in medical innovation, biotechnology, diagnostics, pharmaceuticals, and medical technology. These businesses may provide capital-appreciation potential in addition to income.

Discount to Net Asset Value

At a 5.71% discount on July 10, investors were effectively paying $18.99 for approximately $20.14 of underlying assets.

A discount can provide a more attractive entry point, although there is no guarantee that it will narrow. Discounts can remain wide—or become wider—for extended periods.

The Major Risks

THQ’s high yield comes with meaningful risks.

Distribution Sustainability

The distribution relies heavily on realized gains rather than recurring portfolio income. During weak healthcare markets, the fund may have fewer gains available to support the payment.

Healthcare Concentration

THQ is concentrated in a single economic sector. Regulatory changes, drug-pricing policies, unsuccessful clinical trials, reimbursement pressures, or changes in government healthcare spending could negatively affect several holdings simultaneously.

Leverage

As of July 9, 2026, approximately 21% of THQ’s portfolio was effectively leveraged. Leverage can increase income and amplify gains when investments perform well, but it can also magnify losses and increase financing expenses.

Private and Biotechnology Investments

Some of THQ’s holdings are smaller, privately held, or development-stage healthcare companies. These investments may be more difficult to value and can experience greater volatility than established pharmaceutical or medical-device companies.

Discount Volatility

Because THQ is a closed-end fund, its market price is determined by investor demand and may move independently of the portfolio’s NAV. An investor can lose money from both a decline in the underlying portfolio and a widening discount.

THQ Compared With Traditional Dividend Stocks

THQ should not necessarily be viewed as a replacement for high-quality dividend-growth stocks.

Companies such as Johnson & Johnson, Abbott Laboratories, or established healthcare REITs may offer lower current yields, but their dividends are generally supported by recurring business cash flow. They may also provide more predictable dividend-growth potential.

THQ takes a different approach. It provides a much higher current payout by combining portfolio dividends, interest, realized capital gains, return of capital, and leverage.

This can make THQ appropriate as a higher-yield satellite position within a diversified income portfolio rather than as the portfolio’s primary foundation.

Final Assessment

THQ offers dividend investors a rare combination: healthcare exposure, monthly distributions, a double-digit yield, and the potential to purchase its portfolio below net asset value.

The fund may be attractive to investors who:

• Want immediate monthly income.

• Understand how closed-end funds operate.

• Can tolerate fluctuations in market price and NAV.

• Want healthcare exposure without selecting individual companies.

• Are comfortable with leverage and a distribution funded partly through capital gains.

More conservative investors may be concerned by the difference between THQ’s distribution rate and its longer-term NAV return. The presence of return of capital and reliance on realized gains also mean the monthly payment should not be treated as equivalent to a fully covered corporate dividend.

Overall, THQ appears best suited for investors who prioritize high current income and are willing to actively monitor the fund’s NAV, distribution composition, discount, leverage, and healthcare-sector performance.

Its yield is certainly appealing—but with THQ, the quality and sustainability of the distribution matter just as much as its size.

Data in this article is current through July 10, 2026, unless otherwise stated. This article is provided for informational purposes only and does not constitute financial, investment, tax, or legal advice. Investors should conduct their own research and consider their objectives and risk tolerance before buying any security.